On 27 October 2021, the CAT published five summaries of Notices of Appeal brought by Allergan, Advanz Pharma, Cinven, Auden Mckenzie and Intas Pharmaceuticals, all challenging the CMA’s findings that the pharma companies infringed the Chapter 1 and Chapter 2 Prohibitions under the Competition Act 1998 in their supply of hydrocortisone tablets (see UK Competition July- August Newsletter). The CMA is expected to file a consolidated defence by 1 December 2021.